The FDA’s adoption of ICH E2B(R3) represents more than just a technical format change – it’s a fundamental shift in how safety data is reported. While regulators like the EMA and PMDA have been using E2B(R3) for years, the FDA’s region-specific implementation introduces a new level of complexity that many organizations may not be fully prepared for. That’s where MultiVigilance comes in. Purpose-built to handle this transition, MultiVigilance helps pharmacovigilance and clinical safety teams move forward with confidence, speed, and full compliance.

Why the FDA’s E2B(R3) Format Demands a Different Approach

The FDA’s version of E2B(R3) goes well beyond global requirements. It introduces extensive regional customizations—particularly for IND safety reports and medical device submissions—significantly expanding the volume and granularity of data to be submitted.

Key challenges include:

• New and expanded data fields
• Complex input structures
• S.-specific terminologies (NDC, EDQM, IMDRF)
• Strict validation rules and submission logic unique to the FDA
• Subtle but impactful XML structure differences from global standards

Failure to meet these standards could result in submission rejections, delays, or compliance risks.

From Regulatory Burden to Operational Advantage

This isn’t just a regulatory compliance task—it’s an operational transformation. Success under E2B(R3) requires new workflows, deeper coordination between clinical and safety teams, and a sharper focus on data quality. With the FDA introducing new ICSR report types—including summary and aggregate reports—organizations must elevate their readiness across the board.

Terminology accuracy, for example, is no longer optional—it’s a regulatory expectation. Coding errors can jeopardize submissions and delay time-to-market.

Built for the Complexity—Optimized for the Future

LifeSphere MultiVigilance is engineered to meet the demands of FDA E2B(R3) head-on:

• Intelligent automation reduces manual effort by pre-populating region-specific fields and product data.
• FDA-aligned validation logic ensures every ICSR meets submission requirements the first time.
• Seamless integration with key reference dictionaries (NDC, EDQM, IMDRF) eliminates the need for custom workarounds.
• Ready-to-use IND reporting support accelerates implementation and operational readiness.

Best of all, LifeSphere MultiVigilance is built to evolve—future-proofing your safety operations for ongoing regulatory change.

The April 2026 Deadline Is Approaching. Are You Ready?

With the FDA’s enforcement deadline on the horizon, now is the time to act. Whether you’re migrating from legacy systems or looking to optimize your existing R3 processes, LifeSphere MultiVigilance delivers the automation, compliance, and confidence your teams need to stay ahead.

This isn’t just about meeting a mandate—it’s about transforming how your organization manages safety.

Partner with ArisGlobal. Power your transition with LifeSphere MultiVigilance.